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Diabetes among tuberculosis 
patients and its impact 
on tuberculosis treatment 
in South Asia: a systematic review 
and meta‑analysis
Sanju Gautam1, Nipun Shrestha2*, Sweta Mahato1, Tuan P. A. Nguyen1, Shiva Raj Mishra3 & 
Gabriele Berg‑Beckhoff4
The escalating burden of diabetes is increasing the risk of contracting tuberculosis (TB) and has 
a pervasive impact on TB treatment outcomes. Therefore, we conducted this systematic review 
and meta‑analysis to examine the burden of diabetes among TB patients and assess its impact on 
TB treatment in South Asia (Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, India, Pakistan, 
and Sri Lanka). PubMed, Excerpta Medica Database (EMBASE), and CINAHL databases were 
systematically searched for observational (cross‑sectional, case–control and cohort) studies that 
reported prevalence of diabetes in TB patients and published between 1 January 1980 and 30 July 
2020. A random‑effect model for computing the pooled prevalence of diabetes and a fixed‑effect 
model for assessing its impact on TB treatment were used. The review was registered with PROSPERO 
number CRD42020167896. Of the 3463 identified studies, a total of 74 studies (47 studies from India, 
10 from Pakistan, four from Nepal and two from both Bangladesh and Sri‑Lanka) were included 
in this systematic review: 65 studies for the prevalence of diabetes among TB patients and nine 
studies for the impact of diabetes on TB treatment outcomes. The pooled prevalence of diabetes in 
TB patients was 21% (95% CI 18.0, 23.0; I2 98.3%), varying from 11% in Bangladesh to 24% in Sri‑
Lanka. The prevalence was higher in studies having a sample size less than 300 (23%, 95% CI 18.0, 
27.0), studies conducted in adults (21%, 95% CI 18.0, 23.0) and countries with high TB burden (21%, 
95% CI 19.0, 24.0). Publication bias was detected based on the graphic asymmetry of the funnel plot 
and Egger’s test (p < 0.001). Compared with non‑diabetic TB patients, patients with TB and diabetes 
were associated with higher odds of mortality (Odds Ratio (OR) 1.7; 95% CI 1.2, 2.51; I2 19.4%) 
and treatment failure (OR 1.7; 95% CI 1.1, 2.4; I2 49.6%), but not associated with Multi‑drug resistant 
TB (OR 1.0; 95% CI 0.6, 1.7; I2 40.7%). This study found a high burden of diabetes among TB patients in 
South Asia. Patients with TB‑diabetes were at higher risk of treatment failure and mortality compared 
to TB alone. Screening for diabetes among TB patients along with planning and implementation of 
preventive and curative strategies for both TB and diabetes are urgently needed.
Tuberculosis (TB) is the largest infectious disease killer in the  world1. The South Asian region which consists of 
eight low and middle-income nations, namely Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, 
and Sri Lanka alone shares for nearly 44% of the world TB  cases1 and a high burden of TB mortality (681,975 
deaths), 38% of the worldwide  burden2. The high burden of TB is further intricated by the growing prevalence of 
various risk factors such as acquired immunodeficiency syndrome, kidney disease, malnutrition, and diabetes in 
South Asia; and are further compounded by the health system-related and patient related factors such as access, 
diagnosis and treatment  completion3,4.
The burden of cardiometabolic diseases, particularly diabetes has become a major health problem in South 
Asian countries, with an expected rise in diabetes prevalence of more than 151% between 2000 and  20205,6. 
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Moreover, some studies have indicated that South Asians are at higher risk of developing cardiometabolic dis-
eases including diabetes compared to other ethnic  groups5,7. Diabetes has also been found to escalate the risk of 
contracting TB by three  folds8,9. Likewise, diabetes is associated with a higher risk of failure in TB treatment or 
relapse, failure in culture conversion at 6-months and 2-months10 and deaths in TB patients, more precisely pul-
monary TB  patients11. Besides, a systematic review showed that there is an increased risk of mortality (RR = 1.89 
(95% CI 1.52–2.36), combined outcome failure and death (RR = 1.69 (95% CI 1.36–2.12), and relapse (RR = 3.89 
(95% CI 2.43–6.23) among patients with TB-diabetes comorbidity than TB only  patients12. It is therefore foresee-
able that this surge in the diabetes prevalence will increase vulnerability to TB infection and negative treatment 
outcomes among those with active TB  disease13–15. The exact mechanism of how diabetes comorbidity impact 
health outcomes in TB patients has not been elucidated yet. However, there is some evidence for the negative 
impact of diabetes comorbidity on the TB treatment  outcome10,11,16. Several mechanisms have been postulated 
for the diabetes impact on the TB treatment outcome that includes altered immunological  response17,18, increased 
insulin resistance due to anti-tuberculosis drugs particularly, Rifampicin and impaired immunity due to diabetes 
 itself19. However, evidence summarizing the impact of diabetes on TB treatment outcomes from the South Asian 
population is limited.
World Health Organization member countries have agreed upon an ambitious target to achieve 25% reduction 
in TB incidence and 75% reduction in TB mortality between 2015 and 2025, and 90% reduction in TB incidence 
and 95% reduction in TB mortality by  203520. This ambitious target cannot be achieved unless the escalating bur-
den of risk factors such as diabetes is properly addressed. Some systematic reviews have summarized the burden 
of diabetes among TB patients at the global and regional  levels3,9. Previous systematic review by Noubiap et al. 
which reported global prevalence of diabetes among TB patients, did not provide comprehensive evidence from 
South Asian countries; failing to include many studies from India and reporting no studies from Afghanistan, 
Bhutan, Maldives and  Nepal3. Therefore, a much larger study with updated information on both epidemiology 
and impact of TB-diabetes is urgently needed in the South Asia region.
This study will, therefore, examine the existing literature on the prevalence of diabetes and its impact on 
treatment outcomes among TB patients which can inform policymakers in devising strategies for integrated 
care of TB and diabetes at the national and regional levels.
Results
Study selection. Of the 3463 articles retrieved (3295 articles for estimating the prevalence of diabetes 
among TB patients and 168 articles for assessing the impact of diabetes among TB treatment outcome), 65 
articles were found eligible for assessing the prevalence of diabetes among TB patients and nine for assessing the 
impact of diabetes on TB treatment outcomes as shown in the figures. (Supplementary Fig. 1). Included studies 
were observational studies conducted in at least one of the South Asian Association for Regional Cooperation 
(SAARC) countries in any age group or any gender and have reported prevalence of diabetes among tuberculo-
sis patients or provide data that allowed computation of the impact of DM on tuberculosis treatment outcome.
Study characteristics. The main characteristics of the studies included in the review are summarized in 
Supplementary Table 2. In total, 65 studies with 49,792 TB patients were included in the pooled prevalence for 
diabetes in tuberculosis patient, out of which 47 studies were from  India13,21–67, 10 from  Pakistan68–77, four from 
 Nepal78–81 and two studies each from  Bangladesh82,83 and Sri-Lanka84,85. However, there were no studies from 
Bhutan, Maldives, and Afghanistan. Almost all studies used consecutive sampling (73.8%), were hospital-based 
(93.8%), and collected data prospectively (76.9%). Regarding study design, two were case–control studies, 20 
were of cohort design and the rest were cross-sectional studies. The sample size of studies varied from 101 to 
8109 and the mean age of the participants (TB patients) ranged from 29–53.3 years. All studies included both the 
male and female participants and most of the studies included only adult TB patients (84.6%), while the remain-
ing 10 studies (15.4%) included both adult and children TB patients as their participants. In a larger propor-
tion of studies, diabetes was diagnosed by measuring blood glucose levels (random, fasting, and/or 2-h OGTT) 
(86.2%) while in the remaining studies (13.8%) the diagnosis was based on self-reporting, records, treatment 
cards and use of antidiabetic medications. Similarly, most of the studies used medical records, chest radiography, 
and sputum smear microscopy for identifying TB patients.
Assessment of risk of bias. The risk of bias of the included studies was evaluated using the Newcastle 
Ottawa scales (NOS) adapted from Alebel et al.9 with slight modification. Only one-third of the studies (34) 
were judged to have a low risk of bias. Most studies were judged at a high risk of bias for item number three of 
the selection category description of the non-response rate. Only 12 studies have adequately described the non-
response rate in the  study21,24,27,32,37,38,40,51,56,64,79,83 (Supplementary Table 3). The mean NOS score assessing the 
impact of diabetes among TB treatment outcome was seven (of a possible nine points), suggesting that the high 
quality of the studies was included in the meta-analysis (Supplementary Table 6).
A meta‑analysis of the prevalence of diabetes among TB patients. A meta-analysis of 65 stud-
ies using the random-effect model showed that the overall pooled prevalence of diabetes among TB patients in 
South Asian countries was 21% (95% CI 18, 23) with-high heterogeneity (I2 = 98.28%, p-value < 0.001). The low-
est prevalence of diabetes among patients with TB was 4% (95% CI 2.0, 6.0) which was reported from a study in 
 Nepal80 and the highest was 66% (95% CI 61.0, 71.0) reported by a study in  India32 (Fig. 1). In a sensitivity analy-
sis, including only the studies with low risk of bias, there was no difference in the pooled prevalence of diabetes 
in tuberculosis patients (23%; 95% CI 19.0, 27.0, I2 = 98.85) (Supplementary Fig. 3). A visual analysis of the fun-
nel plot showed some evidence of publication bias which was further confirmed by Egger’s test (p-value < 0.001).
3
Vol.:(0123456789)
Scientific Reports |         (2021) 11:2113  | https://doi.org/10.1038/s41598-021-81057-2
www.nature.com/scientificreports/
Findings from subgroup analysis showed that there is a wide difference between the pooled prevalence across 
the countries; the lowest being 11% (95% CI 10.0, 12.0) in Bangladesh to the highest 24% (95% CI 21.0, 27.0) in 
Sri-Lanka. Similarly, a large variation in the diabetes prevalence was also seen within countries, ranging from 5% 
Figure 1.  Forest plot for the pooled prevalence of diabetes among tuberculosis patients in South Asia.
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(95% CI 3.0, 8.0)13 to 66% (95% CI 61.0, 71.0)32 in India, 8%, (95% CI 4.0, 14.0)76 to 40% (95% CI 38.0, 41.0)68 in 
Pakistan, 4% (95% CI 2.0, 6.0)80 to 25% (95% CI 21.0, 29.0)78 in Nepal and 8% (95% CI 7.0, 10.0)82 to 13% (95% 
CI 11.0, 14.0)83 in Bangladesh (Table 1). Furthermore, a small reduction in the pooled prevalence of diabetes 
among the TB population was observed in the pooled analysis of studies limited to more than 300 participants 
only (19.0%, 95% CI 16.0, 22.0) and studies conducted within 2010–2015 (19.0%, 95% CI 16.0, 22.0). Addition-
ally, the prevalence was higher in studies including only adults (21.0%, 95% CI 18.0, 23.0). Nevertheless, the 
subgroup analysis still showed considerable heterogeneity (> 90%) (Table 1). Meta-regression showed that the 
diabetes prevalence is associated with the period of data collection (R2 = 5.47%), diabetes diagnostic method 
(R2 = 9.96%) and the proportion of men in the sample (R2 = 10.74%). However, none of the covariates (countries, 
population, site, source of data collection, TB burden in the country) were found to be significant predictors to 
the observed heterogeneity in the meta-regression (Supplementary Table 4).
Impact of diabetes on TB treatment outcomes. A total of nine met the eligibility criteria out of the 
168 initially identified studies. Studies were excluded if they were not in English language, were conducted 
among people with severe illness or conditions and were not from SAARC countries. However, only eight stud-
ies were included in the meta-analysis23,41,48,53–55,86,87, a single study that reported hazard ratio (HR) was not 
included in the pooled analysis. All of the included studies were from India and had cohort design; out of which 
six were  retrospective23,41,48,53,55,87 and the remaining three were prospective cohort  studies54,55,86. The sample 
size for the non-diabetic TB population ranged from 120 to 2127, whereas for diabetic TB patients, it was 12 to 
667. Additionally, the proportion of male participants in studies ranged from 44.6 to 77.69% and the average age 
of the participants was between 35 and 49 years old. The detailed characteristics of the included studies can be 
found in the supplementary (Supplementary Table 5).
Of eight studies, one study reported culture conversion at 2/3 months88, three studies reported mortality, 
failure, and conversion to MDR-TB41,55,89, two reported mortality and  failure48,55, one reported mortality in 
terms of  HR87, one reported a conversion to MDR-TB53 and 1 study reported recurrence as the TB treatment 
 outcome54 (Supplementary Table 6).
Table 1.  Subgroup analysis of the prevalence of diabetes in people with tuberculosis.
Overall Number of studies Prevalence (95% CI) % I2 Pheterogenity
Total 65 21% (18.0–23.0) 98.28  < 0.0001
By period
Before 2010 6 22.0% (11.0–33.0) 97.87  < 0.0001
2010–2014 36 19.0% (16.0–22.0) 97.68  < 0.0001
2015 and onwards 23 23.0% (17.0–28.0) 98.81  < 0.0001
By sample size
Less than 300 25 23.0% (18.0–27.0) 94.66  < 0.0001
300 or more 40 19.0% (16.0–22.0) 98.79  < 0.0001
By TB burden in-country
Low 6 16.0% (8.0–24.0) 97.15  < 0.0001
High 59 21.0% (19.0–24.0) 98.33  < 0.0001
By site
Hospital-based 61 21.0% (18.0–23.0) 98.30  < 0.0001
Population-based 3 17.0% (9.0–26.0) – –
Both 1 24.0% (22.0–25.0) – –
By population
Adults 55 21.0% (18.0–23.0) 97.99  < 0.0001
Adults and children 10 19.0% (13.0–25.0) 98.72  < 0.0001
By country
Bangladesh 2 11.0% (10.0–12.0) – –
India
     Southern Region 26 27% (22.0–31.0) 98.10  < 0.0001
    Western Region 8 15% (10.0–21.0) 96.24  < 0.0001
    Eastern Region 2 17% (13.0–20.0) – –
    Northern Region 3 14% (12.0–17.0) – –
    North-Eastern Region 5 21% (11.0–30.0) 96.68  < 0.0001
    Multiple Regions 3 14% (10.0–19.0) – –
Total pooled (India) 47 22.0% (19.0–25.0) 97.92  < 0.0001
Nepal 4 12.0% (4.0–20.0) 96.70  < 0.0001
Pakistan 10 19.0% (11.0–27.0) 99.18  < 0.0001
Sri-Lanka 2 24.0% (21.0–27.0) –  > 0.0001
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Mortality. The pooled estimates demonstrated that TB patients with diabetes had an approximately two-fold 
higher risk of mortality as compared with non-diabetic TB patients (Odds ratio (OR) = 1.74, 95% CI 1.21, 2.51; 
I2 19.43%; low heterogeneity) as shown in Fig. 2. However, a single study, could not be pooled in the analysis as 
it reported only HR (1.30, 95% CI 0.16, 10.49), but still confirmed the higher risk of mortality as compared to 
non-diabetic TB  patients87.
Treatment failure. The pooled result across all five studies reported a higher risk of treatment failure in TB 
participants with diabetes compared to non-diabetic TB participants (OR 1.65, 95% CI 1.12, 2.44) as shown in 
Fig. 3. There was moderate heterogeneity (I2 = 49.63%) across the pooled studies.
Multi drug‑resistant tuberculosis. The pooled effect size demonstrated a nonsignificant difference in risk for 
MDR-TB between diabetic and non-diabetic TB participants (Fig. 4).
Culture conversion and recurrence. There was only one study reporting culture conversion as the treatment out-
come which reported no significant association between diabetes and culture conversion (OR 0.32, 95% CI 0.10, 
1.05)88. Additionally, a single study by Velayutham et al.54 reported the recurrence as the outcome. Compared 
with non-diabetic TB patients, diabetic TB patients had 0.53 lower odds (95% CI 0.32, 0.87) of recurrence after 
the TB treatment.
Discussions
Our study found a higher prevalence of diabetes (21%, 95% CI 18.0, 23.0) among TB patients compared to Asia 
(17%; interquartile range 11.4, 25.8)90, and global prevalence, (15·4%, 95% CI 14.1, 16.6)3, and a marginally 
higher prevalence compared to a previous study from Southeast Asia (19%, 95% CI 16.2, 21.9)3. These variances 
Figure 2.  Forest plot for the association between diabetes and mortality among tuberculosis patients in South 
Asia.
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could be elucidated by the fact that most of the Asians as compared to other populations of a known body mass 
index have higher visceral fat or adiposity, poor glycemic control, decreased pancreatic beta-cell mass and have 
reduced insulin  secretion91–94.
There was high heterogeneity in the pooled estimates of diabetes prevalence among the TB patients across the 
studies (I2 = 98.28%, p-value < 0.001). In the subgroup analysis by the country, a wide variation in the diabetes 
prevalence in TB patients was found with the highest prevalence reported in Sri Lanka (24%) and the lowest 
prevalence reported in Bangladesh (11%). Furthermore, the prevalence of diabetes among TB patients also varied 
widely within countries itself from 5 to 66% in India, from 8 to 40% in Pakistan, from 4 to 25% in Nepal and 
from 8 to 13% in Bangladesh (Fig. 3). The variation in the prevalence of diabetes comorbidity among TB patients 
closely aligns with a higher burden of diabetes overall, and regional variation in diabetes prevalence: Southern 
states like Kerala and Tamil Nadu have a higher prevalence of diabetes compared to other states in  India95 (Sup-
plementary Fig. 4). Additionally, the prevalence of diabetes among the TB population was slightly higher in the 
sample size of less than 300 (23.0%, 95% CI 18.0, 27.0) compared to the sample size of more than 300 (19.0%, 
95% CI 16.0, 22.0). Furthermore, the prevalence was higher in studies including only adults (21.0%, 95% CI 
18.0, 23.0) and studies carried out in the high-risk countries of TB burden as classified by WHO (21.0%, 95% 
CI 19.0, 24.0) than the countries with a low risk of TB burden (16.0%, 95% CI 8.0, 24.0). In the meta-regression 
proportion of males in the study sample, diabetes diagnostic method and studies conducted in and after the 
year 2015 were found to explain the observed heterogeneity to some extent. The differences in dietary habits and 
diabetes screening methods may contribute to further variations in the prevalence of diabetes among TB patients 
within these  countries11,96,97. These variances are also linked to overall variability in the caseloads of TB-diabetes 
co-morbidity, family history, and ethnic-mix of the population in South Asia. Despite the heterogeneity, these 
data suggest a higher prevalence of diabetes among TB patients in the South Asian population consistent with 
previous  studies3,98 and warrants urgent attention from stakeholders.
Impact of diabetes on tuberculosis treatment outcome. Data from this review showed that TB-
diabetes patients have 1.74 (95% CI 1.21, 2.51) times higher odds of mortality compared to non-diabetic TB 
patients. This increased risk of mortality in TB diabetes comorbidity corroborates with previous systematic 
 reviews12,99. These results depict a worrying picture of the effect of diabetes among TB patients especially among 
countries where the prevalence of diabetes is increasing rapidly. However, this finding was driven by only a single 
study in the meta-analysis and remaining four studies in the meta-analysis and a single study that could not be 
pooled in the meta-analysis showed no association. This is apparently due to absence of large longitudinal stud-
ies assessing impact of diabetes on TB treatment.
Additionally, TB patients with diabetes seemed to have a higher likelihood of treatment failure (OR = 1.65; 
95% CI 1.12, 2.44). This finding is buttressed by previous studies where there was a higher failure rate in diabetic 
than non-diabetic TB  patients100–103. Contrary to our results, Singla et al.104 and Khanna et al.105 reported no 
difference in TB treatment outcomes among diabetic and non-diabetic TB patients, which can be ascribed to 
small sample size and the retrospective design of these  studies105.
We found no evidence that diabetes increases the risk of MDR-TB consistent with a previous  study103. How-
ever, our study findings are contrary to results from another systematic review, which showed increased odds of 
MDR-TB among the TB- diabetes  population99,106–110. However, the absence of association in our review might 
be due to the limited number of studies. Further, there was only one study that reported relapse and sputum 
conversion, however, the number of studies from other regions have reported increased odds of sputum conver-
sion and relapse/recurrence103,111,112 among patients with TB-diabetes co-morbidity.
Strength and limitations. The findings of this study need to be interpreted with caution due to the inher-
ent limitations of the included studies as well as data availability for pooled analysis. We could not conduct 
subgroup analysis for various covariates that might be important for increased diabetes risk in TB patients such 
Figure 4.  Forest plot for the association between diabetes and multidrug-resistant tuberculosis among 
tuberculosis patients in South Asia.
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as age, education, and family income. Additionally, there is a possibility of differential misclassification of the 
outcome if blood glucose was examined before the initiation of TB treatment, as, TB infection can induce hyper-
glycemia that could be misdiagnosed as  diabetes113. Various diagnostic techniques used for ascertaining diabetes 
in the TB population might have induced the risk of under or over-representation of diabetes patients among 
studies.
Also, a retrospective cohort study that had no data on glycemic control before the onset of TB made it arduous 
to ascertain the clinical manifestations of TB and temporal relationship (causal pathway) of glycemic  control16. 
Other limitations include the lack of information on cause-specific deaths. This might have exaggerated the 
results since it cannot be assumed that increased deaths imply increased mortality due to TB; the deaths could 
be ascribed to any other comorbidities and factors inherent in the health system of a country.
A large number of studies included were from India, therefore the pooled estimates might not be generaliz-
able to the whole South Asian region. Additionally, one study by Nandakumar et al.41 for assessing the impact 
of diabetes on tuberculosis treatment outcome contributed > 80% of the weight in our effect estimates which 
might have skewed our results.
Despite these limitations, to the best of our knowledge, this is the first systematic review and metanalysis 
to assess the prevalence of diabetes among TB patients and its impact on tuberculosis treatment in South Asia. 
The study was conducted adhering to the rigorous methodological protocol, designed according to the PRISMA 
guidelines for systematic reviews. The searches for eligible studies were conducted in electronic databases: Med-
line, Embase, and CINAHL which cover a wide range of peer-reviewed articles using broad search terms which 
ensured that relevant studies were unlikely to be missed. Additionally, references in the included studies and 
existing reviews were screened and forward citation tracking were done to identify relevant studies.
Conclusion
In summary, the study found that a quarter of TB patients in South Asia also have diabetes comorbidity: 11% 
in Bangladesh to 24% in Sri-Lanka. These variations were seen not only across the countries but also within 
countries like India. Furthermore, the findings of this review show poorer treatment outcomes among diabetic 
TB patients compared to those without diabetes comorbidity; this was especially true for outcomes such as 
mortality and treatment failure. Considering the escalating burden of diabetes mellitus, especially in countries 
where the burden of TB still high, the provision of comprehensive screening programs might be beneficial for 
early diagnosis and treatment of diabetes among TB patients and vice-versa.
Methods
Search strategy and selection criteria. This systematic review and meta-analysis was done adhering 
to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)  guidelines114,115. Eligible 
studies reporting the prevalence of diabetes among TB patients were identified using a comprehensive search of 
peer-reviewed articles in PubMed, Embase, and CINAHL from January 1980 to 30 July 2020. The search strategy 
included all the commonly used terms for diabetes and TB as well as individual country names. For assessing the 
effect of diabetes on the TB treatment outcome, a separate search was conducted and search limited to articles 
published since 1980, as Rifampicin was included in the TB treatment regimen only since  198099. Besides this, 
supplemental searches were conducted by examining the reference list of all the included studies and systematic 
reviews on this topic. The detailed search strategy for all the databases are included in the supplementary files 
(Supplementary Table 1).
Inclusion and exclusion criteria. All relevant studies were screened for eligibility independently by two 
authors (SG, SM) and any discrepancies were resolved through discussion with the third author (NS). For inclu-
sion, studies had to fulfill the following criteria: (1) Study population: Cross-sectional and other observational 
studies conducted in at least one of the South Asian Association for Regional Cooperation (SAARC) countries 
i.e. Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan in any age group or any gender. (2) Expo-
sure: Diabetes diagnosed either by a physician or identified based on measured random plasma glucose, fasting 
plasma glucose, oral glucose tolerance tests according to WHO (World Health Organization) guidelines, HbA1c, 
anti-diabetic drugs, or self-reports (3). Comparison: For prevalence estimate of diabetes in TB patient those 
studies which were conducted among TB patients and reported the number of diabetic cases and TB patient 
population. For TB-treatment outcome, case–control and cohort studies assessing the difference in the TB treat-
ment outcome between the TB-diabetes group and TB only patients. (4). Outcome: The included studies needed 
to have reported the prevalence of diabetes among patients with TB or provide data that allowed computation 
of the prevalence. For TB treatment outcome, studies needed to either report or provide data for assessing the 
impact of diabetes on at least one of the following five TB treatment outcomes:- treatment failure, mortality, 
relapse, and recurrence along with culture conversion (as a proxy of treatment outcome) and Multi-drug resist-
ant TB (MDR-TB; as a long-term treatment outcome). During searches multiple articles using same dataset 
were also identified, in such cases the most comprehensive article that reported the outcomes considered in this 
review was considered for inclusion.
Exclusion criteria were: (1) Studies having a sample size less than 100 to avoid selection bias from small 
studies. For summarizing the treatment outcome, the studies were excluded if (1) used non-standard TB treat-
ment regimens or different treatment regimens among TB patients with diabetes and without diabetes (2) were 
conducted among people with severe illness or conditions or in TB patients with proven drug resistance at the 
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Data extraction and quality assessment. Two authors independently (SG and SM) extracted the data 
into a piloted data collection form adapted from Alebel et al.9 and Noubiap et al.3 with necessary modifications. 
Extracted data for assessing the prevalence of diabetes among TB patients include characteristics of studies, 
publication date, period of data collection, country included in the study, study design, sampling technique, 
sample size, gender and mean age of participants, diabetic cases among TB patients, method of data collec-
tion, a diagnostic method for TB and diabetes. Similarly, details were recorded regarding the assessment of TB 
treatment outcome, information on the type of outcome, specification of the outcome, wherever applicable, and 
available for assessing the impact of diabetes on TB treatment outcomes. The authors were contacted to provide 
additional information if needed. A modified version adapted from Alebel et al.9 of New castle Ottawa scales 
(NOS) was used to evaluate the quality of the included studies. The NOS scale assess risk of bias in three domains 
and assigns higher points for low risk of bias in each domain with maximum of nine points: (1) selection of study 
groups (four points); (2) comparability of groups (two points); and (3) ascertainment of outcomes (three points) 
. Studies with six points or higher were deemed to at of low risk of bias and consequently of high  quality9.
Statistical analysis. A high heterogeneity in prevalence estimates is expected when pooling the studies 
conducted in different  populations116. However, the aim of this study is to summarize the prevalence of diabetes 
in TB patient in South Asia which can be then used to inform the likely prevalence of diabetes in TB patients 
in SAARC countries with similar population characteristics where no primary estimates are  available117. The 
random-effect model was used to pool the prevalence of diabetes among TB patients, considering the likelihood 
of heterogeneity between studies which was estimated using the I2 statistic. Generally, I2 values greater than 70% 
suggest high  heterogeneity118. The subgroup analysis was conducted according to the country, sample size (less 
than 300 or more than 300), study site (hospital-based/population-based/both), TB burden in the country (high/
low), and by populations (adults/adults and children) for investigating the potential source of heterogeneity. The 
studies with only low risk of bias were pooled in a sensitivity analysis to assess the robustness of the findings. 
Furthermore, a funnel plot was generated to visually assess publication bias and was confirmed by the Eggers 
test. A p-value of less than 0.05 was considered statistically significant. The study-specific variance in prevalence 
was stabilized using the Freeman-Tukey double arcsine transformation for constructing the funnel  plot119. Simi-
larly, the random-effects meta-regression was conducted to investigate the potential sources of heterogeneity.
The treatment outcomes that were assessed were mortality, failure, development of MDR-TB, sputum conver-
sion, and recurrence. The fixed-effect meta-analysis model was used for pooling the estimates of the impact of 
diabetes on TB treatment outcomes. The availability of only a few studies (less than five articles for each outcome) 
and the absence of significant heterogeneity were the reasons for selecting the fixed effect over the random effect 
model. All the analyses were performed in STATA. This systematic review was registered with the International 
Prospective Register of Systematic Reviews (PROSPERO), number CRD42020167896.
Ethical approval and consent to participate. This article is based on previously conducted studies and 
does not contain any studies with human participants or animals performed by any of the authors.
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